This may be attributed to the more common usage of infliximab since it was the first TNF-α inhibitor to receive U.S. Food and Drug Administration (FDA) approval in 1998 for inflammatory bowel disease (IBD) [61]. The gene discussed is TNF; the disease is inflammatory bowel disease.